Market cap of Sonnet BioTherapeutics Holdings Inc. [SONN] reaches 25.41M – now what?


Sonnet BioTherapeutics Holdings Inc. [NASDAQ: SONN] price surged by 2.50 percent to reach at $0.01. The company report on December 17, 2021 that Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30th, 2021 and provided a business update.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Pankaj Mohan, Ph.D., Founder and CEO commented, “This year has been incredibly exciting for Sonnet. We identified a new bispecific candidate, SON-1410, and were granted patent-protection for our FHAB technology. Additionally, we generated compelling new data to progress our therapeutic pipeline, including successful preclinical studies for SON-1010 and SON-080, which set the stage for future clinical studies. We believe this positions us well for continued growth and advancement of our pipeline in 2022.”.

A sum of 2973388 shares traded at recent session while its average daily volume was at 2.73M shares. Sonnet BioTherapeutics Holdings Inc. shares reached a high of $0.4449 and dropped to a low of $0.4013 until finishing in the latest session at $0.42.

The one-year SONN stock forecast points to a potential upside of 86.75. The average equity rating for SONN stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Sonnet BioTherapeutics Holdings Inc. [SONN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SONN shares is $3.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SONN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for Sonnet BioTherapeutics Holdings Inc. is set at 0.04 The Price to Book ratio for the last quarter was 0.75, with the Price to Cash per share for the same quarter was set at 0.45.

SONN Stock Performance Analysis:

Sonnet BioTherapeutics Holdings Inc. [SONN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.78. With this latest performance, SONN shares dropped by -27.57% in over the last four-week period, additionally sinking by -73.51% over the last 6 months – not to mention a drop of -81.48% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SONN stock in for the last two-week period is set at 27.34, with the RSI for the last a single of trading hit 23.67, and the three-weeks RSI is set at 31.00 for Sonnet BioTherapeutics Holdings Inc. [SONN]. The present Moving Average for the last 50 days of trading for this stock 0.5738, while it was recorded at 0.4350 for the last single week of trading, and 1.1600 for the last 200 days.

Insight into Sonnet BioTherapeutics Holdings Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Sonnet BioTherapeutics Holdings Inc. [SONN] shares currently have an operating margin of -5187.36. Sonnet BioTherapeutics Holdings Inc.’s Net Margin is presently recorded at -5165.97.

Return on Equity for this stock declined to -197.66, with Return on Assets sitting at -135.09.

Sonnet BioTherapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 4.30.

>> 7 Top Picks for the Post-Pandemic Economy <<

Sonnet BioTherapeutics Holdings Inc. [SONN] Insider Position Details

There are presently around $1 million, or 4.70% of SONN stock, in the hands of institutional investors. The top three institutional holders of SONN stocks are: VANGUARD GROUP INC with ownership of 1,776,753, which is approximately 153.231% of the company’s market cap and around 3.24% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 496,757 shares of the stock with an approximate value of $0.2 million in SONN stocks shares; and BLACKROCK INC., currently with $75000.0 in SONN stock with ownership of nearly 0% of the company’s market capitalization.

Positions in Sonnet BioTherapeutics Holdings Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 10 institutional holders increased their position in Sonnet BioTherapeutics Holdings Inc. [NASDAQ:SONN] by around 1,736,291 shares. Additionally, 3 investors decreased positions by around 1,845 shares, while 8 investors held positions by with 1,053,924 shares. The mentioned changes placed institutional holdings at 2,792,060 shares, according to the latest SEC report filing. SONN stock had 4 new institutional investments in for a total of 179,413 shares, while 2 institutional investors sold positions of 1,001 shares during the same period.